Dinesh Khanna, ACR 2020: Ziritaxestat in Cutaneous Systemic Sclerosis
touchIMMUNOLOGY caught up with Dinesh Khanna (University of Michigan, Ann Arbor, MI, USA) to discuss the results of the NOVESA Phase 2a study of ziritaxestat in cutaneous systemic sclerosis (NCT03798366).
His abstract entitled ‘A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)’ was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- What are the unmet needs in the treatment of systemic sclerosis (SSc)? (0:15)
- What is ziritaxestat and what is the rationale for its use in the treatment of patients with diffuse cutaneous SSc? (0:47)
- Could you tell us a little about the NOVESA study and its findings? (1:48)
- What have these findings taught us about the role of the autotaxin pathway in the pathogenesis of SSc skin disease and how will they influence future research? (4:18)
Disclosures: Dinesh Khanna has received grant support from NIH, Immune Tolerance Network, Bayer, BMS, Horizon, and Pfizer; acted as a Consultant for Acceleron, Actelion, Abbvie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Gilead, Galapagos, Genentech/Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics; and has stocks in Eicos Sciences, Inc (less than 5%) and a Leadership/Equity position as Chief Medical Officer, CiviBioPharma/Eicos Sciences, Inc.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
